Loading
Nucleic-acid Targeted Therapy / RNA, Viral · Journal article
Emerging Microbes & Infections · August 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical in vivo proof-of-concept study investigating a novel intranasal FEN1-hpDNA nanomedicine co-administered with baicalein in SARS-CoV-2-infected mice. The authors report a partial reduction in viral load but do not provide quantitative effect sizes, sample sizes, or statistical comparisons with untreated or comparator-treated controls.
In vivo preclinical study in mice. SARS-CoV-2-infected mice. Intervention: Intranasal nanomedicine formulation comprising FEN1, hairpin-structured DNA probes (hpDNAs) targeting nucleocapsid RNA and Cathepsin L mRNA, formulated in silica cross-linked micelles (SCLMs), co-administered with baicalein.
Multi-target intranasal formulation combining FEN1-hpDNA targeting viral nucleocapsid RNA and host Cathepsin L mRNA elicited partial viral load reduction in SARS-CoV-2-infected mice Co-administration of baicalein was examined to improve cellular biodistribution of the nanomedicine formulation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding does not support clinical practice changes. Further development requires controlled efficacy studies, pharmacokinetic characterization, toxicity assessment, and ultimately human clinical trials before any clinical application can be considered.
Early-stage in vivo study in mice using a novel intranasal nanomedicine formulation with a surrogate endpoint (viral load reduction), lacking control group details, clinical outcomes, and adequate sample size reporting.
As stated by the source record.
This preclinical finding does not support clinical practice changes. Further development requires controlled efficacy studies, pharmacokinetic characterization, toxicity assessment, and ultimately human clinical trials before any clinical application can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Although the acute phase of the SARS-CoV-2 pandemic has subsided, viral persistence and variant evolution continue to challenge existing antiviral strategies. Here, we investigated an intranasal nanomedicine formulation comprising flap-endonuclease 1 (FEN1) and a panel of hairpin-structured DNA probes (hpDNAs), which we designed to concurrently target the highly conserved nucleocapsid RNA and host-derived Cathepsin L mRNA. This dual-targeting approach aims to interfere with both viral genetic integrity and the host-dependent entry pathway. Replacing conventional siRNA/sgRNA with stable, economical hpDNAs may improve the practicality of nucleic acid-based antivirals. Additionally, the co-administration of the anti-inflammatory agent baicalein was examined to assess its potential to improve the nanomedicine's cellular biodistribution. Our portable intranasal drop, a multi-target treatment co-administered with baicalein, elicited a partial reduction in the viral load in mice infected with SARS-CoV-2, suggesting that this multi-target strategy may offer an alternative antiviral modality for further development.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.